An official website of the United States government.

This is not the current EPA website. To navigate to the current EPA website, please go to This website is historical material reflecting the EPA website as it existed on January 19, 2021. This website is no longer updated and links to external websites and some internal pages may not work. More information »

NPDES Draft Control Mechanism for GSK-Hamilton Pharmaceuticals in Montana

This is a draft pretreatment control mechanism. The GSK-Hamilton facility is a campus with buildings that support pharmaceutical manufacturing of MPL and QS-21 adjuvants. These adjuvants are shipped offsite to other GSK locations for vaccine formulation. The GSK-Hamilton facility is owned by Corixa Corporation dba GlaxoSmithKline Vaccines. The facility discharges to the City of Hamilton POTW. Authorization for discharge in the draft documents is limited to only those outfalls specifically listed in the notice of discharge requirements.

You may need a PDF reader to view some of the files on this page. See EPA’s About PDF page to learn more.